<DOC>
	<DOCNO>NCT01650324</DOCNO>
	<brief_summary>The study perform assess safety , tolerability , pharmacokinetic ( PK ) pharmacodynamic ( PD ) property single oral dos DBPR108 healthy male subject .</brief_summary>
	<brief_title>A Single-dose Phase 1 Study DBPR108 Healthy Male Subjects</brief_title>
	<detailed_description>This study represent first administration dipeptidyl peptidase 4 ( DPP4 ) inhibitor DBPR108 human evaluate safety , tolerability , pharmacokinetic ( PK ) pharmacodynamic ( PD ) property follow single oral dos healthy subject . DPP4 validate drug target treatment human type 2 diabetes . Objectives study characterize safety tolerability single dose DBPR108 ; characterize single dose PK DBPR108 plasma urine ; characterize single dose PD DBPR108 glucose , glucagon , dipeptidyl peptidase 4 activity , total active form glucagon-like peptide-1 ( GLP-1 ) plasma level insulin C-peptide serum level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male suitable vein cannulation repeat venipuncture , must able swallow study drug intact ; Aged 20 45 year ( inclusive ) screen visit ; Able provide write informed consent willing comply study protocol procedure restriction . Has body weight less 50 kg and/or body mass index ( BMI ) less 18 kg/m2 great 30 kg/m2 screen visit ; Has creatinine clearance ( Ccr ) less 80 mL/min screening ; Is good general health judge Investigator base routine medical history , vital sign , physical examination , ECG , laboratory test , urinalysis screen visit admission residential period ; Is normoglycemic defined fast glucose le 70 mg/dL ( 3.9 mmol/L ) great 100 mg/dL ( 5.5 mmol/L ) ; Has platelet count le 150,000/ÂµL ; Uses antihyperglycemic agent screen admission residential period ; Has history presence disease condition know interfere absorption , distribution , metabolism , excretion drug screen visit admission residential period ; Has clinically significant psychiatric , renal , hepatic , cardiovascular , gastrointestinal , neurologic disease screen admission residential period ; Is smoker and/or use nicotinecontaining product within last 6 month prior screen current study and/or history alcohol abuse ; Has donate blood participate another clinical study within 8 week precede day admission ; Excessive intake caffeinecontaining drink food ( ie , coffee , tea , chocolate , PAOLYTA B Liq , WHISBIH Liq , cola [ 6 unit caffeine per day ] ) ; Use drug enzymeinducing property St. John 's Wort within 4 week prior first administration investigational product ; Has use prescription nonprescription medication ( except occasional use paracetamol nasal spray ) herbal remedy vitamins mineral within 2 week 5 halflives drug , whichever longer , prior dose end study ; Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration investigational product ; Male subject unwilling use barrier contraception addition partner use another method contraception , duration study 3 month dose ; Has positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) , human immunodeficiency virus ( HIV ) ; Has receive blood transfusion and/or HCV infection ; Positive result screen drug abuse , alcohol , cotinine ( nicotine ) screen admission ; Involved planning conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>DBPR108</keyword>
	<keyword>DPP4</keyword>
	<keyword>Diabetes</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Incretins</keyword>
</DOC>